Prenetics Global Limited (PRE) Raises 2026 Guidance to $220M-$230M
Prenetics Global Limited (PRE) increased its 2026 revenue guidance to $220M-$230M and initiated 2027 IM8 revenue guidance of $400M or more. The 2027 forecast excludes potential revenue from upcoming product launches. No prior guidance was provided for comparison.
How this was made

The 30-second read
Why it matters
The upgraded revenue guidance signals stronger growth momentum, which could attract growth‑oriented investors.
Market read
Guidance lift is the primary catalyst for PRE's near‑term price action.
What to watch
Potential execution risk for upcoming product launches not reflected in the guidance.
Background
Prenetics Global Ltd (NASDAQ:PRE) is a consumer health and diagnostics company that previously reported Q3 2026 results on Aug 26, 2026.
Ticker impact
Prenetics raised its full-year 2026 revenue guidance to $220M-$230M and set 2027 IM8 revenue guidance of $400M+.
potential upside as investors price in higher revenue expectations
The new guidance is fresh information not previously disclosed and materially raises revenue expectations.
Market effects
Higher guidance may lift sentiment in the consumer health and diagnostics sector.
Positive for Asian biotech/healthcare equities where Prenetics has exposure.
Limited to investors tracking growth-stage health tech stocks.
Counterpoint
If the guidance is overly optimistic, future earnings could miss expectations, leading to a sell‑off.
Key entities
- companyPrenetics Global Limited
Consumer health and diagnostics firm issuing new revenue guidance.


